Simtra BioPharma Solutions
↗Bloomington, Indiana, USA
Simtra BioPharma Solutions is a premier global contract development and manufacturing organization (CDMO) specializing exclusively in sterile injectables. Formerly the BioPharma Solutions business unit of Baxter International, the company became an independent entity in 2023 following a $4.25 billion acquisition by private equity firms Advent International and Warburg Pincus.
The company provides a comprehensive range of services including formulation development, lyophilization cycle optimization, and clinical to commercial-scale fill/finish operations. Simtra is recognized for its expertise in handling complex and highly potent compounds, such as cytotoxics and antibody-drug conjugates (ADCs), and operates world-class manufacturing facilities in the United States and Germany.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CDMO (Contract Development and Manufacturing)
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$600M-$1B
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Acquired
Total Raised:$4250M
Investors:Advent International, Warburg Pincus
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Service Provider)
Modalities:Small molecule, Biologics, ADC, Vaccines, Cytotoxics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Baxter Oncology GmbH
Key Partnerships:MilliporeSigma (Strategic alliance for ADC manufacturing), Cook Group (Property acquisition for expansion)
COMPETITION
Position:Leader
Competitors:Catalent, Lonza, Thermo Fisher Scientific (Patheon), Samsung Biologics, Recipharm
LEADERSHIP
Key Executives:
Franco Negron - CEO
Raymond Guidotti - COO
Mike Schaefers - Chief Commercial Officer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Simtra BioPharma Solutions. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.